Investor Presentation Full Year 2021
46
Investor presentation Full year 2021
Novo NordiskⓇ
Two fixed dose combinations entered phase 2 in the second half
of 2021 in people with type 2 diabetes
Phase 2 trial design for cagrilintide in combination with
with T2D
10.5%
⚫ Met +/- SGLT2i
semaglutide investigated in T2D
Randomisation
(1:1:1)
90 participants
↓
•
HbA1c 7.5-
Cagrilintide OW + Semaglutide OW
•BMI >27 kg/m2
Cagrilintide OW + placebo OW
Semaglutide OW + placebo OW
--+-------
Dose escalation
16 weeks
Treatment maintenance FU 5
16 weeks
weeks
Phase 2 trial design for semaglutide in combination
~500 participants
with T2D
Age ≥ 18-75
years
⚫ BMI: 25-39.9
kg/m2
⚫HbA1c: 7.0-10.0%
Diet/exercise +
metformin
with GIP
Dose ratio 1:1 Semaglutide OW + GIP OW
Placebo
Dose ratio 1:3 Semaglutide OW + GIP OW
Placebo
Dose ratio 1:5 Semaglutide OW + GIP OW
Placebo
Dose ratio 1:9 Semaglutide + GIP OW
Placebo
GIP OW
Semaglutide OW
Dose escalation
10 weeks
Maintenance period
24 weeks
FU 5
weeks
Trial objective: Compare the effect on glycaemic control and body weight of
cagrilintide in combination with semaglutide vs semaglutide in patients with
T2D
Primary endpoint: Change in HbA1c (%-point)
Next steps: 37-week trial was initiated in Q3 2021
Trial objective: Compare the effect on glycaemic control and body weight of
semaglutide in combination with GIP vs semaglutide and vs GIP
Primary endpoint: Change from baseline to week 34 in HbA1c (%-point)
Next steps: 39-week trial was initiated in Q4 2021
T2D: Type 2 diabetes; HbA₁: Haemoglobin A1c; BMI: Body mass index; FU: Follow-up; OAD: Oral anti-diabetic; GIP: Gastric inhibitory peptide; OW: Once-weeklyView entire presentation